Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple Turns 50: From Garage Startup to AI Crossroads 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
, a range of dry surrogate microorganisms - EconoTimes)
DIJON, France, Oct. 07, 2016 -- Novolyze, a fast-growing food biotechnology company, announces the global launch of its new range of products: SurroNov(TM) www.novolyze.com
SurroNov(TM) is a range of innovative surrogate microorganisms that mimic the behavior of food pathogens (Salmonella, Listeria, Cronobacter sakazakii etc). As they are non-pathogenic, SurroNov(TM) products can be directly used in-plant to validate the efficacy of preventive controls on the microbial reduction of food products.
The range was officially presented at IAFP Annual Meeting in St. Louis. MO from July 29 to August 4, 2016. The first surrogate introduced is a strain used for the validation of low water activity foods (spices, nuts, powders, pet food etc) for which the prevention and control of microbiological hazards is a key food safety challenge. Our surrogate has been tested on numerous food processes, most of them thermal processes such as extruders, dryers, roasters and ovens. The first projects performed using SurroNov(TM) products showed highly correlative results, confirming the strong interest of the food industry for stabilized, dry & ready to use surrogate microorganisms.
The launch of SurroNov(TM) is an important step for Novolyze: It is the result of several years of R&D as well as intensive financial and human capital investments. SurroNov(TM) products are patented innovations based on Novolyze Dry Surrogate Technology. In parallel, the company continues its development plan, focused on the research of new strains for different kinds of food products.
Jena Robers, VP Business Development at Novolyze : 'First collaborations with several multinational food companies have been initiated and we are proud that our innovations received such a positive feedback. We are convinced that SurroNov(TM) surrogate microorganisms are a key tool for food companies to comply with FSMA Final Rule for Preventive Controls for Human Food. Our team is now focused on the evolution of the range and on the launch of other strains to complete our portfolio. Our ambition is to offer innovative solutions to our partners in order to better control microbiological hazards and improve food safety of processed foods.'
Contact :
Pierre-Olivier BEAL Business Development Manager
T (USA) : +1 (617) 500-8536
www.novolyze.com
